USFDA APPROVED DULAGLUTIDE IN PRIMARY & SECONDARY PREVENTION IN ASCVD.

Dear my friends and fellow Colleagues, Here is an update on GLP1 Analogue DULAGLUTIDE. Dulaglutide becomes the first Antidiabetic agent to be approved by USFDA for reducing the risk of CV events for both primary & secondary prevention populations. The new approval is based on results of REWIND TRIAL. EMA has already approved Dulaglutide for this indication. EMA European Medical Agency. February, 2020. Regards and thanks, Dr Sepuri Krishna Mohan.

6 Likes

LikeAnswersShare
Informative
Thank you doctor
0
Thanks Dr Sepuri Krishna Mohan for the update on Glucagon like Peptide 1 receptor agonist - DULAGLUTIDE , which significantly reduces the risk of CV events in T2DM. Although a good drug if used in combination with dietary control and exercise but cost factor is there for common man As it is weekly used as S/C injection in maintenance dose of 0.75 - 1.5 mg which nearly costs Rs 2500 .- common man may find it costly. As diabetes is so common in affluent section of society- it a good option particularly in IHD patients. It should not be used in T1DM , diabetic ketoacidosis and in family history of medullary thyroid carcinoma and MEN- 2 as it increases the risk of malignancy in such patients
Valuable opinion
0

View 1 other reply

Nice post and helpful one.thanks.
Thank you doctor
0
Eductive post
Thank you doctor
0

Cases that would interest you